Suppr超能文献

伊布利特的电生理学与药理学

Electrophysiology and pharmacology of ibutilide.

作者信息

Naccarelli G V, Lee K S, Gibson J K, VanderLugt J

机构信息

Penn State Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania, USA.

出版信息

Am J Cardiol. 1996 Oct 17;78(8A):12-6. doi: 10.1016/s0002-9149(96)00560-7.

Abstract

Ibutilide fumarate is a new class III intravenous antiarrhythmic agent indicated for the acute termination of atrial fibrillation and flutter. Ibutilide prolongs repolarization in the atria and ventricle by enhancing the inward depolarizing, slow sodium current, a unique mechanism of action for a class III agent. Atrial refractoriness is prolonged with no evidence of reverse use dependence. Ibutilide may also block the delayed rectifier current, but this does not appear to be clinically relevant. In vitro and at high doses, ibutilide may shorten action potential duration, although this effect has not been noted clinically. Ibutilide can cause torsades de pointes in a rabbit model of proarrhythmia dependent on the formation of early afterdepolarizations. However, it causes less proarrhythmia than sotalol, dofetilide, or sematilide in this model. The pharmacokinetics of ibutilide are linear, its extravascular distribution is rapid and extensive, while its systemic clearance is high (elimination half-life 3-6 hours). Eight metabolites are formed by the liver, only one of which is slightly active. QT prolongation is dose dependent, is maximal at the end of the infusion, and returns to baseline within 2-4 hours following infusion. The pharmacokinetic and electrophysiologic characteristics of ibutilide are complementary in that any risk of proarrhythmia is made manageable by a short half-life. Almost all reported cases of drug-induced torsades de pointes ventricular tachycardia associated with ibutilide have occurred within 40 minutes of starting the infusion. Nevertheless, clinicians using ibutilide can further reduce the chance of torsades de pointes by being very familiar with the criteria for patient selection, and by being prepared to treat it should it occur. When used with full knowledge of its potential risks, ibutilide is a very effective intravenous agent for the acute termination of atrial fibrillation and flutter and is likely to become a significant treatment option for these arrhythmias.

摘要

富马酸伊布利特是一种新型III类静脉用抗心律失常药物,用于心房颤动和心房扑动的急性转复。伊布利特通过增强内向去极化慢钠电流来延长心房和心室的复极,这是III类药物独特的作用机制。心房不应期延长,无反向使用依赖性证据。伊布利特也可能阻断延迟整流电流,但这在临床上似乎并不相关。在体外及高剂量时,伊布利特可能缩短动作电位时程,尽管临床上未观察到这种效应。在依赖早期后除极形成的心律失常兔模型中,伊布利特可引起尖端扭转型室性心动过速。然而,在该模型中,它引起的心律失常比索他洛尔、多非利特或司美利特少。伊布利特的药代动力学呈线性,其血管外分布迅速且广泛,而其全身清除率较高(消除半衰期为3 - 6小时)。肝脏可形成8种代谢产物,其中只有一种略有活性。QT间期延长呈剂量依赖性,在输注结束时最大,输注后2 - 4小时内恢复至基线水平。伊布利特的药代动力学和电生理特性相辅相成,即心律失常的任何风险都可通过短半衰期进行控制。几乎所有报道的与伊布利特相关的药物性尖端扭转型室性心动过速病例都发生在开始输注后的40分钟内。尽管如此,使用伊布利特的临床医生可以通过非常熟悉患者选择标准,并在心律失常发生时做好治疗准备,进一步降低尖端扭转型室性心动过速的发生几率。在充分了解其潜在风险的情况下使用时,伊布利特是一种非常有效的静脉用药物,用于心房颤动和心房扑动的急性转复,并且可能成为这些心律失常的重要治疗选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验